Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
The Jikei University operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active for this portfolio. This count reflects the current workload for the university's patent applications in this specific field.
The prosecution is distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that each of the 2 pending office actions is being reviewed by a different examiner in a different specialized unit of the patent office. The involvement of 2 distinct art units shows that the university's technology spans multiple technical classifications within the Biotechnology & Pharmaceuticals sector.
BEHARRY, ZANNA MARIA is the busiest examiner, with 1 busiest examiner pending office action. This examiner is responsible for 1 of the 2 total pending office actions. Because the workload is split between 2 distinct examiners, the university must manage different examination styles. Practitioners should prepare for the specific nuances of BEHARRY, ZANNA MARIA and the other assigned examiner to successfully navigate these 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEHARRY, ZANNA MARIA | 1 | 25.0% | +56.3% |
| HOFFMAN, SUSAN COE | 1 | 54.2% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836116 | Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte | BEHARRY, ZANNA MARIA | — |
| 17602644 | THERAPEUTIC AGENT FOR FIBROSIS, INFLAMMATION, AND/OR AGING DISEASE | HOFFMAN, SUSAN COE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836116 | Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte | BEHARRY, ZANNA MARIA | — |
| 17602644 | THERAPEUTIC AGENT FOR FIBROSIS, INFLAMMATION, AND/OR AGING DISEASE | HOFFMAN, SUSAN COE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836116 | Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte | BEHARRY, ZANNA MARIA | 1632 | §102§112 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 17602644 | THERAPEUTIC AGENT FOR FIBROSIS, INFLAMMATION, AND/OR AGING DISEASE | HOFFMAN, SUSAN COE | 1655 | §101§102§103 | Non-Final OA | — | Pending | Oct 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Jikei University has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Zanna Maria Beharry has the most, with 1 of The Jikei University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
